Septerna (NasdaqGM:SEPN) FY Conference Transcript

Summary of Septerna's Conference Call Company Overview - Company: Septerna - Industry: Biopharmaceuticals, specifically focused on GPCR (G protein-coupled receptor) drug discovery Key Points and Arguments Pipeline and Drug Development - Septerna is advancing its pipeline, particularly with the MRGPRX2 program, which has shown promising phase 1 data indicating differentiation from existing drugs and effective pharmaceutical properties, including the complete abrogation of the inflammatory cascade [1][4] - The company is also developing an oral PTH (parathyroid hormone) agonist, SEP-479, aimed at treating hyperparathyroidism, which is expected to enter clinical trials soon [1][21] MRGPRX2 Program - The MRGPRX2 program is focused on a negative allosteric modulator, SEP-631, which has demonstrated a potent effect in preclinical models, showing complete knockdown of skin extravasation in response to agonists [5][10] - Phase 1 trial results indicate that SEP-631 was well-tolerated with no serious adverse events, a half-life of approximately 24 hours, and no food effect, suggesting potential for once-daily oral dosing [13][18] - The upcoming phase 2 trial for chronic spontaneous urticaria is planned for the second half of the year, with a focus on dose-ranging and placebo-controlled design [20][31] SEP-479 Program - SEP-479 is a selective small molecule agonist for the PTH1 receptor, aimed at patients who have lost their parathyroid glands, leading to low calcium levels [21][22] - Preclinical studies have shown that SEP-479 can normalize serum calcium levels and has a long projected human half-life of 40-80 hours, with IND-enabling studies nearing completion [23][27] - The phase 1 trial for SEP-479 is set to begin in Australia, with a focus on safety and efficacy in healthy volunteers [28][44] Market Opportunity - Both programs target significant unmet medical needs, with MRGPRX2 involved in various conditions such as chronic spontaneous urticaria, asthma, and atopic dermatitis, while SEP-479 addresses hyperparathyroidism [19][21] - The company is well-capitalized, with a cash runway extending into at least 2029, allowing for continued investment in its pipeline [4] Additional Insights - The Native Complex Platform developed by Septerna is designed to unlock difficult GPCR targets, which has led to a robust portfolio of drug candidates [3][4] - The company is exploring multiple indications for its MRGPRX2 antagonist, including pain conditions and rheumatology indications, beyond the initial focus on chronic spontaneous urticaria [20] - The use of innovative technologies, such as the AllergyScope for quantifying skin wheals, highlights Septerna's commitment to advancing clinical trial methodologies [15] Conclusion - Septerna is positioned to make significant advancements in the biopharmaceutical industry with its innovative drug discovery platform and promising pipeline, particularly in the areas of GPCR-targeted therapies and calcium regulation in hyperparathyroidism. The upcoming clinical trials and strong financial backing suggest a positive outlook for the company's future developments.